Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Annalisa Brescia

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Pharmaceutics|February 27, 2026
Emerging Therapeutic Approaches for Modulating the Intestinal MicrobiotaIlaria Cosimato, Annalisa Brescia, Gianluigi Franci, et al.
Cytotechnology|December 29, 2010
Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditionsAgostina Nardone, Sara Corvigno, Annalisa Brescia, et al.
Cancers|June 24, 2022
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case SeriesPietro Torre, Annalisa Brescia, Giorgio Giurato, et al.
Angewandte Chemie (International Ed. in English)|July 2, 2015
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent PolypharmacologyBrendan Frett, Francesca Carlomagno, Maria Luisa Moccia, et al.
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Plos One|June 6, 2015
Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinaseMarialuisa Moccia, Qingsong Liu, Teresa Guida, et al.
European Journal of Medicinal Chemistry|May 21, 2025
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitorPhuc Tran, Marialuisa Moccia, Xiuqi Wang, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Pharmaceutics|February 27, 2026
Emerging Therapeutic Approaches for Modulating the Intestinal MicrobiotaIlaria Cosimato, Annalisa Brescia, Gianluigi Franci, et al.
Cytotechnology|December 29, 2010
Long-term cultures of stem/progenitor cells from lobular and ductal breast carcinomas under non-adherent conditionsAgostina Nardone, Sara Corvigno, Annalisa Brescia, et al.
Cancers|June 24, 2022
Mucosal-Associated Invariant T Cells in T-Cell Non-Hodgkin Lymphomas: A Case SeriesPietro Torre, Annalisa Brescia, Giorgio Giurato, et al.
Angewandte Chemie (International Ed. in English)|July 2, 2015
Fragment-Based Discovery of a Dual pan-RET/VEGFR2 Kinase Inhibitor Optimized for Single-Agent PolypharmacologyBrendan Frett, Francesca Carlomagno, Maria Luisa Moccia, et al.
Scientific Reports|August 10, 2021
Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinasesMarialuisa Moccia, Donglin Yang, Naga Rajiv Lakkaniga, et al.
Journal of Medicinal Chemistry|April 17, 2020
Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent PolypharmacologyMarialuisa Moccia, Brendan Frett, Lingtian Zhang, et al.
Plos One|June 6, 2015
Identification of Novel Small Molecule Inhibitors of Oncogenic RET KinaseMarialuisa Moccia, Qingsong Liu, Teresa Guida, et al.
European Journal of Medicinal Chemistry|May 21, 2025
Discovery of N-(3-fluorophenyl)-2-(4-((7-(1-methyl-1H-pyrazol-4-yl)quinazolin-4-yl)amino)phenyl)acetamide as the first orally active selective aurora kinase B inhibitorPhuc Tran, Marialuisa Moccia, Xiuqi Wang, et al.
Pageof 1